Objective: Individuals with Parkinson disease are more likely to develop melanoma, and melanoma patients are reciprocally at higher risk of developing Parkinson disease. Melanoma is strongly tied to red hair/fair skin, a phenotype of loss-of-function polymorphisms in the MC1R (melanocortin 1 receptor) gene. Loss-of-function variants of MC1R have also been linked to increased risk of Parkinson disease. The present study is to investigate the role of MC1R in dopaminergic neurons in vivo. Methods: Genetic and pharmacological approaches were employed to manipulate MC1R, and nigrostriatal dopaminergic integrity was determined by comprehensive behavioral, neurochemical, and neuropathological measures.
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Results: MC1R
e/e mice, which carry an inactivating mutation of MC1R and mimic the human redhead phenotype, have compromised nigrostriatal dopaminergic neuronal integrity, and they are more susceptible to dopaminergic neuron toxins 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Furthermore, a selective MC1R agonist protects against MPTP-induced dopaminergic neurotoxicity. Interpretation: Our findings reveal a protective role of MC1R in the nigrostriatal dopaminergic system, and they provide a rationale for MC1R as a potential therapeutic target for Parkinson disease. Together with its established role in melanoma, MC1R may represent a common pathogenic pathway for melanoma and Parkinson disease. ANN NEUROL 2017; 81:395-406 P atients with Parkinson disease (PD), one of the most common neurodegenerative diseases, generally have reduced risk of developing almost all types of cancer, with one notable exception-melanoma, a malignant tumor of melanin-producing cells in skin.
1,2 A large number of epidemiological studies have reported that occurrence of melanoma is higher than expected among subjects with PD, and melanoma patients are reciprocally more likely to develop PD. 1, 2 Although well documented since the 1970s, mechanisms underlying this association between PD and melanoma remain largely unknown. Recent epidemiological studies further demonstrated the positive, bidirectional link not only in the patients themselves but also in their relatives, 3, 4 suggesting a possible genetic basis for the association between the two seemingly distinct conditions. A cyclic adenosine monophosphate-stimulating Gprotein-coupled receptor (GPCR), melanocortin 1 receptor (MC1R) contributes to the regulation of skin physiology through the melanin synthetic pathway as well as pigmentation-independent mechanisms.
skin protection and is sufficient to enhance melanoma formation. 10, 11 Furthermore, MC1R e/e mice display greater oxidative damage in skin, suggesting an oxidative stress-mediated mechanism in carcinogenesis. 11 In addition to skin melanocytes, other tissue and cell types that express MC1R include adrenal tissue, immunocytes, endothelial cells, 12 and possibly human astrocytes 13 and periaqueductal gray neurons, 14 suggesting functions of MC1R extending beyond those in skin. In an analysis of 2 large prospective cohorts led by our epidemiologist collaborators, we found that red hair individuals and individuals homozygous for the red hair-associated Arg151Cys allele of Cys were associated with an increased risk for PD. 15 The association was substantiated by another study linking PD with an alternative red hair MC1R variant in an independent cohort. 16 Although other studies [17] [18] [19] [20] did not replicate a significant MC1R-PD association, which may be attributable to technical or population differences across studies, 21 MC1R has nevertheless emerged as having a potential role at the interface of melanoma and PD.
To explore such a role of MC1R in dopaminergic neurons and therefore a biological basis for the PD-melanoma link, we first assessed expression of MC1R in dopaminergic neurons of the substantia nigra (SN) in the mouse brain. Redhead MC1R e/e mice were then employed to investigate effects of MC1R inactivation on the nigrostriatal dopaminergic system under basal conditions and in well-established 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of PD. 22 Furthermore, the neuroprotective potential of MC1R stimulation in an MPTP model was explored using a potent, specific MC1R agonist 1-
Materials and Methods

Animals
First reported as an extension in 1993, 9 MC1R e/e mice carry a frameshift mutation due to a deletion of a single nucleotide at position 549. The mutation produces a prematurely terminated, nonfunctioning protein and results in a yellow/red coat in homozygous mice despite being on a C57BL/6J background. [9] [10] [11] Heterozygous (MC1R e/1 ) mice, conversely, do not display melanoma-related skin phenotypes. MC1R e/e mice were backcrossed with C57BL/6J mice from the Jackson Laboratory (Bar Harbor, ME). Homozygous MC1R e/e and littermate wildtype (WT) mice were used for experiments. For effects of MC1R agonist BMS-470539, adult (3 months old) male C57Bl/6J mice were purchased from the Jackson Laboratory.
Animals were maintained in home cages at constant temperature with a 12-hour light/dark cycle and free access to food and water. All experiments were performed in accordance with a protocol approved by the Massachusetts General Hospital Animal Care and Use Committee.
Measurement of Locomotion
Locomotion was assessed using an automated open field recording system (San Diego Instruments, San Diego, CA). Horizontal locomotor activity during the first 60 minutes (7) (8) of the dark phase of the light cycle was recorded and analyzed as described. 24 Ambulation was quantified as sequential breaks in adjacent beams (55mm apart).
MC1R Immunohistochemistry
Naive adult male C57Bl/6J mice were perfused, and brains were postfixed. Following cryoprotection, brains were sectioned. The sections were heated for antigen retrieval 25 
Immunohistochemistry for TH and Stereological Cell Counting
For TH immunohistochemistry in naive mice, the animals were perfused and the brains were postfixed for 48 hours. For TH immunohistochemistry with tissues from dopaminergic toxin experiments, mice were sacrificed by rapid cervical dislocation. The hinder brain block containing midbrain was immediately dissected and fixed for 48 hours. The brains were then cryoprotected, rapidly frozen by immersion in isopentane on dry ice, and sectioned at 30 mm. Sections were processed free-floating. Primary antibody was mouse monoclonal anti-TH (Sigma, #T1299) at 1:800. 26 For TH stereology, a complete set of serial sections were immunostained for TH and counterstained for Nissl. Sections were analyzed stereologically as described. 26, 27 The number of TH-positive (and TH-negative) neurons in the SN on both ANNALS of Neurology sides of each section was counted, and the total number of TH-positive (and TH-negative) neurons on each side (6-OHDA lesion) or both sides of the SN from individual animals was calculated.
Western Blotting
For Western blot analysis of MC1R in total protein, adrenal or brain tissues were obtained. Total protein was extracted and electrophoresed. After transferring, the membrane was blocked in 5% bovine serum albumin and then incubated with the above MC1R antibody at 1:500. 
Determination of Protein Carbonyls
Protein carbonyls in brain tissues were detected using the Oxyblot Protein Oxidation Detection Kit (Millipore, Billerica, MA). 26 Band density was analyzed and normalized with Ponceau staining using the ImageJ system.
Determination of Oxidative DNA Damage
Nuclear DNA was digested enzymatically, and N-labeled standard lesions were added. Lesions were separated by highperformance liquid chromatography (HPLC) and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/ MS/MS) as previously described.
11,30
6-OHDA Lesion
Mice were pretreated with desipramine, and a solution of 6-OHDA (5.0 mg/ml) was infused into the left striatum as previously described. 26 
Rotational Behavior Assessmen
Spontaneous and amphetamine (5mg/kg)-induced rotational behavior was tested at 3 weeks after the 6-OHDA lesion using an automated rotometry system (San Diego Instruments) for 60 minutes as previously described. 26 
MPTP Treatment Regimens
For MPTP toxicity in MC1R e/e mice, a subacute regimen was employed. 31, 32 Mice were administered intraperitoneally (i.p.)
with MPTP-HCl 20mg/kg or saline once daily for 4 consecutive days and sacrificed 7 days after the last MPTP injection. For effects of MC1R agonist BMS-470539 on MPTP toxicity, a single dose of MPTP-HCl (40mg/kg) 31, 32 or saline was injected i.p., and BMS-470539 dihydrochloride (Tocris Bioscience, Bristol, UK) or vehicle (water) was administrated 10 minutes before and 60 minutes after MPTP. Animals were sacrificed 7 days after the injections. The same treatment paradigm was employed to examine whether BMS-470539 changes MPTP metabolism. Mice were sacrificed 90 minutes after MPTP administration.
MC1R Agonist BMS-470539 and Its Pharmacokinetics
Male C57Bl/6J mice were dosed with BMS-470539 (20mg/kg subcutaneously [s.c.]) 23 and sacrificed at 5 time points (n 5 3) from 5 to 120 minutes. BMS-470539 was measured in plasma and brain by LC-MS/MS/MS by Cyprotex (Watertwon, MA).
Measurement of MPTP Metabolite
Striatal 1 methyl-4-phenylpyridinium (MPP 1 ) was measured using HPLC-ultraviolet (UV) as previously described. 33 
Measurement of Dopamine and Metabolites
Dopamine (DA) and metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were determined by standard HPLC with electrochemical detection, as previously described. 26 
Statistical Analysis
All values are expressed as mean 6 standard error of the mean. The difference between two groups was analyzed by Student t test. Multiple comparisons among groups were performed by 1-way or 2-way analysis of variance (ANOVA), and Tukey post hoc test was performed when an overall significance was demonstrated with 1-way ANOVA or a main effect of genotype was demonstrated with 2-way ANOVA. p 0.05 is considered statistically significant.
Results
MC1R Is Expressed in Dopaminergic Neurons of the SN of Adult C57BL Mice
To probe a role of MC1R in dopaminergic neurons of the SN, we first assessed expression of MC1R in naive C57BL/6J mouse brain. Western blot analysis of MC1R immunoreactivity in the striatum and the ventral midbrain revealed a band corresponding to a molecular weight of 35kDa, the known size of MC1R (Fig 1) . Immunohistochemistry demonstrated, in a coronal section of the ventral midbrain, positive staining for MC1R in the SN pars compacta (SNpc), and the staining vanished when antibody peptide was applied or when primary antibody was omitted. e/e mice performed normally (Fig 2A) . We then assessed neurochemical and morphological measures of dopaminergic nigrostriatal neuron integrity 26, 27 in MC1R e/e mice as they age. HPLC coupled with electrochemical detection revealed 16% and 26% reduction in DA content in the striatum of 8-and 14-month-old MC1R e/e mice, respectively, significantly lower than their WT littermates (8 months old, p < 0.05; 14 months old, p < 0.01; see Fig 2) . e/e mice. There is no significant change in the size of either the nigra or individual TH-positive neurons (Fig 2D and quantitative data not shown) .
Increased Oxidative Damage in the Ventral
Midbrain of Adult MC1R e/e Mice Our collaborative team previously reported an oxidative stress mechanism in MC1R-mediated, UV-independent carcinogenesis in skin using MC1R
e/e mice. 11 Oxidative stress has been implicated in neurodegenerative diseases including PD. 34 To determine whether disrupted MC1R e/e mice and WT littermates determined by high-performance liquid chromatography coupled with electrochemical detection (n 5 5, WT and MC1R
e/e at all 3 age points). *p < 0.05, **p < 0.01 versus WT littermates, 1-way ANOVA followed by Tukey post hoc test. (C) Stereological quantification of tyrosine hydroxylase (TH)-positive and TH-negative (Nissl-positive) neurons in substantia nigra pars compacta in MC1R
e/e mice and littermate WT controls (n 5 5, WT and MC1R
e/e 2-and 14-month-old mice; n 5 6, WT and MC1R e/e 8-month-old mice). **p 5 0.01 versus WT littermates, 1-way ANOVA followed by Tukey post hoc test. (D) Representative sets of nigral sections from MC1R
e/e mice and littermate WT controls stained for TH. Cells in the black boxes at indicated age points are shown at higher magnification in the lower panels. Scale bars 5 20 mm.
is associated with changes in oxidative stress in the nigrostriatal system, we assessed protein carbonyls, a marker of oxidative protein damage, by Oxyblot. 26 Increased protein carbonyls were detected in the ventral midbrain (p < 0.05; Fig 3A) but not the striatum (see Fig 3B) of adult (3-6 months old) MC1R
e/e mice compared to littermate WT controls. Oxidative DNA damage markers 8,5 0 -cyclo-2 0 -deoxyadenosine (cdA) and 8,5
0 -cyclo-2 0 -deoxyguanosine (cdG)
were evaluated in MC1R e/e mice using established LC-MS/MS/MS. 11, 30 Increased levels of S-cdA and S-cdG, which lead to A to T and G to A mutations, respectively, were demonstrated in ventral midbrain in adult MC1R
e/e mice (5-8 months old) as compared to WT littermates (p 5 0.036, S-cdA; p 5 0.046, S-cdG; see Fig 3C) . R-cdA did not show a significant difference between the 2 genotypes (13.6 6 0.8 and 12.4 6 1.0 lesions per 10 7 nucleosides, WT and MC1R
e/e ; p > 0.05). There were no significant changes in S-cdA and R-cdA levels in the striatum in adult redhead MC1R
e/e mice compared to WT controls (see Fig 3D) .
MC1R
e/e Mice Are More Susceptible to Dopaminergic Neurotoxin 6-OHDA In humans, loss-of-function variants of MC1R produce red hair/fair skin phenotype and are linked to higher risk of both melanoma 7, 8 and PD. 15, 16 Our collaborative team previously reported the lower threshold for melanoma induction in redhead MC1R e/e mice. 11 To investigate whether the MC1R disruption may contribute to greater susceptibility to PD, we assessed dopaminergic phenotype of redhead MC1R e/e mice in a well-established 6-OHDA model of PD. 22, 26 Adult (6-8 months old) MC1R e/e and >littermate WT mice received unilateral intrastriatal infusion of 10 mg 6-OHDA. This model induces progressive and retrograde degeneration of the nigrostriatal system by a combined effect of reactive oxygen species and quinones. 22 The animals were then assessed for behavioral, neurochemical, and anatomical measures of dopaminergic deficits (Fig 4A) . 26 Comparing to WT littermates,
e/e mice displayed a statistically significant increase in ipsilateral net rotations after stimulation with a DAreleasing agent amphetamine (p < 0.05) despite no difference in spontaneous rotations ipsilateral to the lesion (see Fig 4B) . The greater DA imbalance between ipsilateral and contralateral sides in MC1R
e/e mice was confirmed by HPLC analysis of DA content in the striatum. 6-OHDA induced greater depletion of DA and a further increase in ratio of HVA, a DA metabolite, to DA in the striatum in MC1R e/e mice than WT littermates on the lesioned side (p < 0.01, striatal DA; p < 0.01, HVA/ DA; see Fig 4C) . After normalization for the significant difference in DA on the unlesioned side between the 2 groups of animals (p < 0.01) by expressing it as percentage of contralateral control value, MC1R
e/e mice had 12.8 6 2.1% residual DA on the lesioned side, significantly lower than the residual in WT mice (31.3 6 3.0%; p < 0.01). A more substantial loss of nigral dopaminergic neurons induced by 6-OHDA infusion was demonstrated in MC1R
e/e mice compared to their WT littermates (see Fig   4D) . Stereological cell counts revealed fewer remaining TH-positive neurons on the lesioned side (p < 0.01). The loss of dopaminergic neurons was still greater as a proportion of the unlesioned contralateral side in MC1R e/e mice (32.4 6 4.6%) than in WT (49.8 6 1.6%; p < 0.01; see Fig 4E) , despite reduced numbers on the unlesioned side (p < 0.01), which confirms the compromised dopaminergic integrity of intact MC1R e/e mice as shown in Figure 2 .
These results demonstrate higher suceptibility of redhead MC1R e/e mice to the dopaminergic toxin 6-OHDA.
e/e Mice Are More Susceptible to Dopaminergic Neurotoxin MPTP Exacerbated dopaminergic neurotoxicity was demonstrated in MC1R
e/e mice in another well-established, complementary toxin model of PD. 22, 31 After systemic administration, MPTP enters the brain and is locally converted to its active metabolite MPP
1
, which in turn is selectively transported into dopaminergic neurons, where it exerts toxicity by inhibiting complex I of the mitochondrial electron transport chain. 22, 32 A subacute regimen (20mg/kg MPTP-HCl i.p. once daily for 4 days) induced greater reduction of striatal DA in adult (6-8 months old) MC1R e/e mice than in WT littermates 7 days after the last MPTP administration (p < 0.01; Fig  5A) . Even with normalization to saline-treated control mice to account for basal differences between the 2 control groups (p 5 0.01), a greater percentage loss of striatal DA in MC1R e/e mice treated with MPTP (82.2 6 2.5%) persisted compared to WT MPTP-treated mice (59.6 6 3.1%; p 5 0.05). MC1R
e/e mice also displayed a 350% increase in DA turnover rate (HVA/DA ratio) after MPTP administration in comparison to a 180% increase in WT littermates (p < 0.05).
Anatomically, TH immunohistochemistry (see Fig  5B) e/e and WT controls at either time point, suggesting MC1R disruption does not alter metabolism of the dopaminergic toxin, and therefore that the exacerbated toxicity in MC1R e/e mice is not due to increased local toxic metabolite after systemic injection (see Fig 5D) .
MC1R Agonist Protects against MPTP-Induced Dopaminergic Neurotoxicity
The compromised nigrostriatal integrity in MC1R e/e mice and their high susceptibility to both 6-OHDA and MPTP suggest a protective role of MC1R signaling in the nigrostriatal dopaminergic system. To further probe this role, we investigated whether pharmacological activation of MC1R protects against MPTP toxicity using a commercially available MC1R agonist BMS-470539. BMS-470539 is a selective, potent MC1R agonist used in the laboratory to understand the role of MC1R in immunomodulation and inflammatory responses. 23, 35 We first determined the pharmacokinetic profile of BMS-470539 in blood and brain in naive C57Bl/6J mice. After systemic injection (20mg/kg s.c.), the concentration of BMS-470539 in plasma peaked at 15 minutes (1,318 6 189ng/ml); in brain it peaked at 30 minutes (18 6 2ng/ml) and remained detectable until at least 120 minutes at 10ng/ml (n 5 3 each time point), corresponding to the agonist's reported median effective concentration of 10ng/ml.
23,35
FIGURE 5: MC1R e/e mice are more susceptible to dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Adult (6-8-month-old) MC1R
e/e and littermate wildtype (WT) mice were injected intraperitoneally (i.p.) with 20mg/kg MPTP-HCl or control vehicle (saline) once daily for 4 days and sacrificed 7 days after the last MPTP administration. (A) Dopamine (DA) in the striatum measured by highperformance liquid chromatography (HPLC) and DA turnover rate (homovanillic acid [HVA]/DA ratio, HVA determined by HPLC) in MPTP or vehicle control (CON) MC1R
e/e mice and WT littermates (n 5 6, WT and MC1R
e/e CON; n 5 8 and 7, WT and MC1R e/e MPTP). *p < 0.05 versus WT CON; #p < 0.05, ##p < 0.01 versus WT MPTP, 1-way analysis of variance (ANOVA) followed by Tukey post hoc test. (B) Substantial loss of TH-positive neurons in the substantia nigra (SN) of an MC1R
e/e mouse after MPTP subacute treatment. (C) Stereological quantification of nigral tyrosine hydroxylase (TH)-positive neurons expressed as absolute counts and percentage of CON group in MC1R
e/e CON; n 5 8 and 7, WT and MC1R
e/e MPTP). **p < 0.01versus WT CON; #p < 0.05, ##p < 0.01 versus WT MPTP, 1-way ANOVA followed by 
Discussion
Epidemiological studies have demonstrated a reproducible bidirectional association between melanoma and PD. [1] [2] [3] [4] They also raised the possibility that the MC1R gene may mediate the association. 15, 16 Built on the previously characterized skin phenotype and melanoma tendency in redhead MC1R e/e mice, 10,11 the present interdisciplinary study identifies a novel role of MC1R in the nigrostriatal dopaminergic system. Our findings demonstrate compromised nigrostriatal dopaminergic system in MC1R e/e mice and their greater susceptibility to local and systemic dopaminergic toxins 6-OHDA and MPTP. Furthermore, pharmacological stimulation of MC1R with a selective agonist attenuates MPTP neurotoxicity. MC1R is expressed in the mouse SN at the protein and mRNA levels. Although juxtaposed to or on the cell surface in some cases, MC1R appears to be located intracellularly, overlapping with cytoplasmic TH fluorescence. Depending on cellular context and cell types, trafficking and localization of GPCRs are tightly regulated and are highly related to their signaling cycle. 36 Immunoreactivity of GPCRs detected inside of the cells may reflect not only technical incorporation of fixation and detergent permeabilization but also functional status of the receptors; for example, they are newly synthesized to be transported to the plasma membrane or internalized following agonist stimulation, 36,37 both often producing a typical punctate staining pattern in the case of MC1R. 38 Relative cell surface expression versus intracellular retention has been reported to correlate with function of MC1R variants. 39 The only neuronal demonstration of MC1R was in cytosome of human periaqueductal gray matter neurons. 14 Intracellular MC1R undergoes oligomerization, which can significantly affect its signaling. 6 It is unclear whether a band at higher molecular weight in both brain tissues and cells that appears to respond modestly to shRNA represents MC1R oligomers. Further characterization of MC1R subcellular distribution and oligomerization would be helpful in deciphering regulation of its function in the SN dopaminergic neurons. Loss-of-function mutant MC1R e/e mice display loss of nigral dopaminergic neurons, reduced striatal DA content, and impaired locomotor activity under basal conditions. These results reveal a significant role of MC1R signaling in maintaining nigrostriatal dopaminergic neuron survival. The trophic influence of MC1R may be due to its direct actions given its expression in dopaminergic neurons. Dopaminergic neuron-specific disruption of MC1R would differentiate whether local MC1R or rather systemic MC1R is responsible. Although MC1R appears to be expressed in other cells in the SN, numbers of nigral TH-negative neurons in MC1R e/e mice remain unchanged. Furthermore, the impaired dopaminergic neuronal integrity is accompanied by increased oxidative damage in the ventral midbrain but not in the striatum. These data suggest that the benefit of MC1R activity may be relatively specific to dopaminergic neurons. However, it is not clear whether MC1R disruption affects only the nigrostriatal system or whether it has broader influence on other dopaminergic cell populations or other central nervous system (CNS) regions. The greater oxidative damage in the midbrain is in agreement with greater oxidative damage in skin in redhead MC1R
e/e mice, 11 supporting a common antioxidant mechanism underlying MC1R-mediated protection in melanocytes and dopaminergic neurons. MC1R e/e mice do not develop dopaminergic deficits until adulthood, indicating agedependent effects of endogenous MC1R signaling on the nigrostriatal dopaminergic pathway. Aging is a primary risk factor for PD. 40 Further investigation is needed to elucidate potential interplay between MC1R and aging and age-related factors including oxidative stress. Nevertheless, the demonstrated nigrostriatal dopaminergic deficits in MC1R e/e mice suggest possible predisposition of these mice to parkinsonism as a result of MC1R disruption.
Redhead MC1R e/e mice display higher susceptibility to 6-OHDA and MPTP, two established neuronal toxins that are commonly used to model dopaminergic neurodegeneration of human PD. 22 Their exacerbated dopaminergic deficits manifest at anatomical, neurochemical, and functional levels after intrastriatal infusion of 6-OHDA or systemic administration of MPTP. The greater susceptibility is likely related to preexisting dopaminergic neuron dysfunction and oxidative damage. In addition, MC1R has been reported to play a central role in inflammatory responses. 23, 34 Oxidative stress and inflammatory responses are known to be involved in 6-OHDA and MPTP toxicity as well as in the pathophysiology of human PD. 23, 34 Dopaminergic neurodegeneration in the context of MC1R disruption may also directly or indirectly involve pigmentation pathway itself. A recent study intriguingly reported increased SN echogenicity in fair skin human subjects. 41 Further investigations are essential to answer important questions regarding downstream intracellular pathways and mediators.
The enhanced vulnerability of redhead MC1R mutant mice in models of PD is consistent in parallel with previously reported lower threshold for melanoma induction in these mice, 11 supporting protective effects of MC1R in both melanocytes and dopaminergic neurons against tumorigenesis and neurodegeneration, respectively. Together with the epidemiological associations of redhead MC1R loss-of-function variants and high risk of melanoma, 7, 8 and possibly high risk of PD, [15] [16] [17] [18] [19] [20] [21] the predisposition of MC1R redhead mutation to melanoma and PD in animal models supports a potential role of MC1R as the biological basis of the melanoma and PD link. Future studies should focus on epidemiological, biological, and clinical interactions between MC1R and PD genetic factors, 2 particularly asynuclein, 42 and leucine-rich repeat kinase 2 (LRRK2). 43 a-Synuclein has been implicated in melanoma pathophysiology, 44, 45 and LRRK2 is the most commonly mutated among PD-associated genes in melanomas. 46 Identifying the role of endogenous MC1R in adult dopaminergic system maintenance and defense presents a unique opportunity to explore the potential of MC1R as a novel therapeutic target for PD. BMS-470539, a selective MC1R agonist 23 with modest blood-brain barrier penetrance, is found to protect dopaminergic neurons against MPTP-induced cell loss in the SN and DA depletion in the striatum. The neuroprotective action of pharmacological MC1R activation provides further evidence that compromised dopaminergic neuronal integrity in redhead MC1R mutant mice and their exacerbated dopaminergic neurotoxicity in models of PD are likely to be MC1R specific. Studies are underway to investigate specificity and efficacy of MC1R neuroprotection by complementary genetic MC1R overexpression. MC1R agonists are currently undergoing clinical testing for depigmentation disorders and an acute phototoxicity related condition. 47, 48 Whether systemic MC1R activation is required for its CNS effects, more CNS-penetrant versions may be needed to target neuronal MC1R for the treatment of PD. Our findings that genetic inactivation of MC1R signaling impairs nigrostriatal dopaminergic neuron survival and that pharmacological activation of MC1R is neuroprotective uncover a protective role of MC1R in the nigrostriatal dopaminergic system. They provide evidence for targeting MC1R as a novel therapeutic strategy for PD. Together with epidemiological associations between MC1R, melanoma, 7, 8 and PD, [15] [16] [17] [18] [19] [20] [21] and the known roles of MC1R in melanocytes and melanoma pathogenesis, 1, 5, 6 0, 11 our data support a shared mechanistic link between melanoma and PD.
